Form 4: Teladoc Legal Chief's Equity Transactions

Teladoc Health's Chief Legal Officer, Adam C. Vandervoort, reported the vesting and acquisition of restricted and performance stock units, alongside a sale of shares to cover tax obligations.

Summary

• Adam C. Vandervoort, Teladoc Health's Chief Legal Officer and Secretary, reported multiple equity transactions.
• On February 27, 2026, Vandervoort acquired a total of 49,590 shares of common stock through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
• These acquisitions included 4,418, 5,350, and 36,610 shares from RSU conversions, and 1,510 and 1,702 shares from PSU conversions.
• Following these acquisitions, his direct beneficial ownership increased to 130,322 shares.
• On March 2, 2026, Vandervoort sold 27,083 shares of common stock at a price of $5.117 per share.
• This sale was conducted to cover tax withholding obligations related to the vesting of his RSU and PSU awards.
• After the sale, his direct beneficial ownership of Teladoc Health common stock stands at 103,239 shares.
• The filing also details several RSU and PSU grants with future vesting schedules, including a new grant of 181,661 RSUs on March 1, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While there's a sale of shares, it's for tax purposes, and the significant acquisition of shares through vesting, coupled with a new RSU grant, indicates continued executive alignment and compensation.

Positives

• Acquisition of 49,590 shares of common stock through the vesting of RSUs and PSUs, indicating successful achievement of performance metrics and continued equity compensation.
• A new grant of 181,661 restricted stock units on March 1, 2026, demonstrates ongoing equity incentives for the Chief Legal Officer.
• The performance stock units acquired on February 27, 2026, were determined based on the issuer's 2025 financial results, suggesting positive performance.

Negatives

• Sale of 27,083 shares of common stock at $5.117 per share to cover tax withholding obligations, which reduces the reporting person's direct ownership.

Future Outlook

The filing indicates future vesting schedules for various equity awards, with restricted stock units and performance stock units continuing to vest in quarterly installments through future dates. A new grant of 181,661 restricted stock units on March 1, 2026, will vest one-third on its first anniversary, with the remainder in eight substantially equal quarterly installments thereafter. Performance stock units acquired on February 27, 2026, based on 2025 financial results, also vest in similar installments.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in a Form 4, provide insights into management's direct equity holdings and compensation structures. While this filing does not directly address broader industry trends in telehealth or digital health, the continued granting and vesting of equity awards to a key executive like the Chief Legal Officer suggest Teladoc Health's ongoing reliance on stock-based compensation to align executive incentives with company performance and shareholder value, a common practice across the technology and healthcare sectors.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) as a significant component of executive compensation is a standard practice across many publicly traded companies, particularly in the technology and growth sectors. Companies like Amwell (AMWL) and Doximity (DOCS), also in the digital health space, similarly utilize equity awards to incentivize executives.
• The sale of shares to cover tax withholding obligations upon vesting is a routine and expected event for executives receiving equity compensation, aligning with practices seen at companies of similar size and industry. This is not indicative of a lack of confidence but rather a standard tax management procedure.

Related Party Transactions

• The transactions involve the Chief Legal Officer and Secretary of Teladoc Health, Inc., which are considered related party transactions as they pertain to executive compensation and equity holdings.

Stakeholder Impact

• Shareholders: The vesting and subsequent sale of shares for tax purposes by a key executive can be viewed as a routine event. The continued granting of equity awards aligns executive incentives with long-term shareholder value.
• Employees: The equity compensation structure for executives may reflect broader compensation practices within the company, potentially influencing employee morale and retention strategies.

Next Steps

• The remaining portions of the granted restricted stock units and performance stock units will continue to vest in substantially equal quarterly installments as per their respective schedules.
• The newly granted 181,661 restricted stock units on March 1, 2026, will vest one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of equity awards and a tax-related sale. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are expected and do not signal a significant shift in insider sentiment or company prospects. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Teladoc Health, TDOC, Adam C. Vandervoort, Form 4, Insider Trading, Restricted Stock Units, Performance Stock Units, Equity Compensation, Stock Sale, Tax Withholding, Officer Transaction